牛牛AI助理已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, has reported positive Phase 2 topline results for its CYB003 program in treating Major Depressive Disorder (MDD), with 79% of patients achieving remission after two doses. The company plans to advance to a Phase 3 trial in early 2024. Cybin's robust intellectual property portfolio includes 40 granted patents and over 170 pending applications. The company also highlighted its upcoming milestones, including additional Phase 2 data, an FDA end-of-Phase 2 meeting, and the initiation of a Phase 2 study of deuterated dimethyltryptamine (dDMT) for Generalized Anxiety Disorder (GAD) in early 2024. Cybin's CEO, Doug Drysdale, expressed confidence in the potential of their clinical programs to revolutionize mental health treatment. The company's DMT program, including CYB004 and SPL028, has completed multiple clinical trials, with Phase 1 topline data expected early in the first quarter of 2024. Cybin aims to initiate a Phase 2 GAD study within the same quarter.
Cybin Inc., a clinical-stage biopharmaceutical company, has reported positive Phase 2 topline results for its CYB003 program in treating Major Depressive Disorder (MDD), with 79% of patients achieving remission after two doses. The company plans to advance to a Phase 3 trial in early 2024. Cybin's robust intellectual property portfolio includes 40 granted patents and over 170 pending applications. The company also highlighted its upcoming milestones, including additional Phase 2 data, an FDA end-of-Phase 2 meeting, and the initiation of a Phase 2 study of deuterated dimethyltryptamine (dDMT) for Generalized Anxiety Disorder (GAD) in early 2024. Cybin's CEO, Doug Drysdale, expressed confidence in the potential of their clinical programs to revolutionize mental health treatment. The company's DMT program, including CYB004 and SPL028, has completed multiple clinical trials, with Phase 1 topline data expected early in the first quarter of 2024. Cybin aims to initiate a Phase 2 GAD study within the same quarter.
臨床階段的生物製藥公司Cybin Inc. 報告了其治療重度抑鬱症（MDD）的 CYB003 項目的 2 期臨床表現良好，79% 的患者在接種兩劑後獲得緩解。該公司計劃在2024年初推進第三階段試驗。Cybin強大的知識產權組合包括40項已獲授權的專利和170多項待處理的申請。該公司還強調了其即將到來的里程碑，包括額外的2期數據、FDA的第二階段末會議以及2024年初啓動的治療廣泛性焦慮症（GAD）的氘化二甲基色胺（ddMT）的2期研究。Cybin的首席執行官道格·德賴斯代爾對他們的臨床項目有可能徹底改變心理健康治療表示信心。該公司的DMT項目，包括 CYB004 和 SPL028，已經完成了多項臨床試驗，第一階段的主要數據預計將在2024年第一季度初發布。Cybin的目標是在同一季度內啓動一項第二階段的GAD研究。
臨床階段的生物製藥公司Cybin Inc. 報告了其治療重度抑鬱症（MDD）的 CYB003 項目的 2 期臨床表現良好，79% 的患者在接種兩劑後獲得緩解。該公司計劃在2024年初推進第三階段試驗。Cybin強大的知識產權組合包括40項已獲授權的專利和170多項待處理的申請。該公司還強調了其即將到來的里程碑，包括額外的2期數據、FDA的第二階段末會議以及2024年初啓動的治療廣泛性焦慮症（GAD）的氘化二甲基色胺（ddMT）的2期研究。Cybin的首席執行官道格·德賴斯代爾對他們的臨床項目有可能徹底改變心理健康治療表示信心。該公司的DMT項目，包括 CYB004 和 SPL028，已經完成了多項臨床試驗，第一階段的主要數據預計將在2024年第一季度初發布。Cybin的目標是在同一季度內啓動一項第二階段的GAD研究。
有用
沒用